• Alias: ON-01910 sodium salt
    • Orally bioavailable dual PI3K/polo-like kinases inhibitor
    • Currently under investigation in phases 2 and 3 clinical trials for MDS and pancreatic cancer
    • Recommended phase 2 dose: 3,120 mg PO daily
    • Half-life: 27 hours
    • Common side effects: Skeletal, abdominal, and tumor pain, nausea, diarrhea
    (Jimeno et al., 2008)
    Other topics in Targeted and Immunotherapy Agents